Unmet Needs in Dermatology: Galderma to Study Nemolizumab in SSc and CPUO
Galderma is launching two new clinical trials to investigate the efficacy and safety of nemolizumab (Nemluvio) in treating patients living with Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO).